Pharmaceuticals , Inc. (Nasdaq: ALNY), a leading RNAi therapeutics
company, announced today that it has initiated its DISCOVERY trial, a
screening study examining the prevalence of transthyretin (TTR)
mutations in patients suspected of having cardiac amyloidosis.
for Alnylam Initiates DISCOVERY, a Screening Study Examining the Prevalence of Transthyretin (TTR) Mutations in Patients Suspected of Having Cardiac Amyloidosis investment picks